These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16949480)

  • 1. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated.
    Kaul S; Zadeh AA; Shah PK
    J Am Coll Cardiol; 2006 Sep; 48(5):914-23. PubMed ID: 16949480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine, folic acid and coronary artery disease: possible impact on prognosis and therapy.
    Djuric D; Jakovljevic V; Rasic-Markovic A; Djuric A; Stanojlovic O
    Indian J Chest Dis Allied Sci; 2008; 50(1):39-48. PubMed ID: 18610689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Group B vitamins as new variables related to the cardiovascular risk].
    Granieri M; Bellisarii FI; De Caterina R
    Ital Heart J Suppl; 2005 Jan; 6(1):1-16. PubMed ID: 15776726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is plasma homocysteine a modifiable risk factor for stroke?
    Hankey GJ
    Nat Clin Pract Neurol; 2006 Jan; 2(1):26-33. PubMed ID: 16932518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J; Kropf S; Luley C; Dierkes J
    Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine, folic acid, B vitamins and cardiovascular risk.
    Blacher J; Safar ME
    J Nutr Health Aging; 2001; 5(3):196-9. PubMed ID: 11458292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.
    B-Vitamin Treatment Trialists' Collaboration
    Am Heart J; 2006 Feb; 151(2):282-7. PubMed ID: 16442889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Homocysteine, folic acid, group B vitamins and cardiovascular risk].
    Blacher J; Czernichow S; Horrellou MH; Conad J; David P; Chadefaux-Vekemans B; Ankria A; Galan P; Hercberg S; Ducimetière P
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):145-52. PubMed ID: 15787307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine: evidence for a causal relationship with cardiovascular disease.
    Scott CH; Sutton MS
    Cardiol Rev; 1999; 7(2):101-7. PubMed ID: 10348972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
    Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
    Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk population.
    Acikel S; Dogan M; Akdemir R
    Int J Cardiol; 2010 Oct; 144(2):326-8. PubMed ID: 19324433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Homocysteine and cerebrovascular disease].
    Sepúlveda-Sánchez JM; Matía-Francés R; Martínez-Salio A; González-de la Aleja-Tejera J; Rodríguez-Peña Marín M; Porta-Etessam J
    Rev Neurol; 2004 Feb 16-29; 38(4):347-58. PubMed ID: 14997460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?
    Lonn E
    Curr Opin Hematol; 2007 Sep; 14(5):481-7. PubMed ID: 17934354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma total homocysteine: instigator or indicator of cardiovascular disease?
    Moat SJ
    Ann Clin Biochem; 2008 Jul; 45(Pt 4):345-8. PubMed ID: 18583617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials.
    Splaver A; Lamas GA; Hennekens CH
    Am Heart J; 2004 Jul; 148(1):34-40. PubMed ID: 15215789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?
    Lazzerini PE; Capecchi PL; Selvi E; Lorenzini S; Bisogno S; Galeazzi M; Laghi Pasini F
    Lupus; 2007; 16(11):852-62. PubMed ID: 17971357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine or renal impairment: which is the real cardiovascular risk factor?
    Potter K; Hankey GJ; Green DJ; Eikelboom JW; Arnolda LF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1158-64. PubMed ID: 18356552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials.
    Antoniades C; Antonopoulos AS; Tousoulis D; Marinou K; Stefanadis C
    Eur Heart J; 2009 Jan; 30(1):6-15. PubMed ID: 19029125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamins and stroke: the homocysteine hypothesis still in doubt.
    Ntaios GC; Savopoulos CG; Chatzinikolaou AC; Kaiafa GD; Hatzitolios A
    Neurologist; 2008 Jan; 14(1):2-4. PubMed ID: 18195649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine-lowering vitamins and cardiovascular mortality: are they really effective?
    Celik T; Iyisoy A; Yuksel UC; Isik E
    Int J Cardiol; 2008 Aug; 128(3):432-3. PubMed ID: 17689750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.